Difference between revisions of "Blinatumomab (Blincyto)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "chemocare.com/chemotherapy/drug-info" to "chemocare.com/druginfo") |
||
| Line 16: | Line 16: | ||
==Patient drug information== | ==Patient drug information== | ||
*Patient information may be found in the [https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/blincyto/blincyto_pi_hcp_english.pdf Blinatumomab (Blincyto) package insert].<ref name=insert></ref> | *Patient information may be found in the [https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/blincyto/blincyto_pi_hcp_english.pdf Blinatumomab (Blincyto) package insert].<ref name=insert></ref> | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/blinatumomab.aspx Blinatumomab (Blincyto) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/blinatumomab.aspx Blinatumomab (Blincyto) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/blinatumomab-patient-drug-information Blinatumomab (Blincyto) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/blinatumomab-patient-drug-information Blinatumomab (Blincyto) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/blinatumomab-patient-drug-information Blinatumomab (Blincyto) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/blinatumomab-patient-drug-information Blinatumomab (Blincyto) patient drug information (UpToDate)]</ref> | ||
Revision as of 23:21, 2 September 2023
General information
Class/mechanism: Bi-specific T-cell engager (BiTE) antibody that targets CD19 (expressed on B cells) and CD3 (expressed on T cells).[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Toxicity management
- Use of Blinatumomab (Blincyto) required participation in the Blincyto Risk Evaluation and Mitigation Strategy (REMS) program until February 2023.
- Immunotherapy toxicity management
Diseases for which it is used
Patient drug information
- Patient information may be found in the Blinatumomab (Blincyto) package insert.[1]
- Blinatumomab (Blincyto) patient drug information (Chemocare)[4]
- Blinatumomab (Blincyto) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2014-12-03: Granted FDA accelerated approval for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (R/R ALL). (Based on MT103-211)
- 2017-07-11: Granted FDA regular approval for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children. (Based on TOWER, MT103-205, and ALCANTARA)
- 2018-03-29: Granted FDA accelerated approval for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. (Based on BLAST)
- 2023-06-21: Converted to regular approval for the treatment of adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with measurable residual disease (MRD) greater than or equal to 0.1%. (Based on COG AALL1331 & Amgen 20120215)
History of changes in EMA indication
- 2015-11-23: Initial authorization
History of changes in Health Canada indication
- 2015-12-22: Initial notice of compliance with conditions
- 2017-04-28: Notice of compliance with conditions for the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.
- 2017-11-16: Conditions were met
- 2019-12-19: Notice of compliance with conditions for the treatment of patients with Philadelphia chromosome-negative CD19 positive B-precursor acute lymphoblastic leukemia (ALL) in first or second hematologic complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
History of changes in PMDA indication
- 2018-09-21: Newly indicated for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
Also known as
- Code names: AMG-103, MEDI-538, MT-103
- Brand name: Blincyto